Nine diŠerent antibodies against P450 isoforms were prepared using puriˆed cytochrome P450s (P450) expressed in E. coli. Puriˆed isozymes were injected into rabbits to raise speciˆc antibody. The resulting antibodies were characterized for their speciˆcity and sensitivity through each particular P450 enzyme-mediated probe reaction.
Introduction
The cytochrome P450 (P450 or CYP) superfamily contributes to the metabolism of xenobiotic chemicals and also endogenous compounds. In the process of drug development, it is important to determine which P450 metabolizes a drug of interest. This is a process referred to as reaction phenotyping. Four approaches in vitro (antibody inhibition, chemical inhibition, cDNA-expressed human P450 enzymes, and correlation analysis by measuring the rate of drug metabolism in several samples of human liver) have been developed for reaction phenotyping 1) and it is generally agreed that more than one approach should be chosen to identify which P450 enzyme is responsible for metabolizing a targeted drug. 2) Among these approaches, the use of speciˆc antibodies to inhibit selected P450 enzymatic activity is most recommended. Due to the ability of antibodies to inhibit speciˆcally and noncompetitively, this method alone can establish which P450 enzyme is responsible for biotransforming a drug of interest. Unfortunately, the utility of this method is limited by the availability of speciˆc antibodies. The development of highly selective antibodies for such a purpose is always hampered by the extensive degree of sequence homology found between isozymes belonging to the P450 superfamily. 3) A number of previous studies have reported the development of antibodies against P450 enzymes using diŠerent methods. Antibodies raised against synthetic peptides that represent small regions of an antigen proved to be particularly suitable for immunoblotting studies 4, 5) but none were found to be potent inhibitors of P450 activity. Another modiˆed attempt involved the production of inhibitory antibody using synthetic cyclic peptides as antigen. 6) However, this is not a general approach since the principal for determining an eŠective cyclic peptide, as antigen, still remains undetermined. On the other hand, monoclonal antibodies, which recognize a single epitope, have also been produced and characterized by enzyme-linked immunosorbent assay (ELISA), by immunoblotting, and also by their inhibitory potency toward cDNA-expressed P450 enzymes. [7] [8] [9] [10] [11] [12] [13] [14] [15] Shou et al. 16) has indicated that many monoclonal antibodies could not distinguish between closely related P450 subfamily members.
To determine the quantitative contribution of a particular P450 enzyme to drug metabolism (reaction  phenotyping), it would be crucial to develop a panel of  selective inhibitory antibodies for the major P450  enzymes, namely CYP1A1, CYP1A2, CYP2A6,  CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 , and CYP3A4, involved in drug biotransformation. In the present study, human P450 enzymes were expressed in a bacterial heterologous expression system, puriˆed to homogeneity, and injected into rabbits for production of inhibitory polyclonal antibodies.
Materials and Methods
Materials: 7-Ethoxyresoruˆn, resoruˆn, 7-hydroxycoumarin, and coumarin were obtained from Aldrich Chemical Company, Inc. (Milwaukee, Wisconsin). Taxol, 6-hydroxytaxol, diclofenac, 4?-hydroxydiclofenac, (S )-mephenytoin, 4-hydroxymephentoin, bufuralol, 1?-hydroxybufuralol, chlorzoxazone, and 6hydroxychlorzoxazone were purchased from Daiichi Pure Chemicals Co. (Tokyo, Japan). Testosterone and 6b-hydroxytestosterone were purchased from Wako Pure Chemical (Osaka, Japan). Complete Freund's adjuvant was obtained from Gibco BRL Products (Rockville, Maryland). Emulgen 911 was a gift from Kao Chemical Co. (Tokyo, Japan). Cholic acid was obtained from Nacalai Tesque (Kyoto, Japan). Pooled human liver microsomes (H0610, lot no. 0010154) from 16 individuals were obtained from XenoTech LLC (Kansas City, Kansas). According to the provided datasheet, the P450 enzyme concentration was 409 pmol W mg and the protein concentration was 20 mg W mL. All other chemical and solvents were of the highest grade commercially available.
Expression of P450 enzymes in Escherichia coli : CYP1A1, CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 were each expressed in an E. coli expression system as described previously. 17) The expressed proteins from several lots were pooled after cell destruction and stored at -809 C until puriˆcation.
Puriˆcation of P450 enzymes: P450 enzymes expressed in E. coli were solubilized in buŠer-A (0.1 M potassium phosphate buŠer, pH 7.2, containing 20z glycerol, 0.2 mM DTT, 0.2 mM EDTA, and 0.25 mM PMSF) containing 0.6z sodium cholate. The solubilization was performed at a concentration of 5 mg protein W mL, and 49 C facilitated by stirring for 30 min, and then the mixture was subjected to centrifugation at 30,000 g for 30 min. The supernatant was collected and applied to an octylamino-Sepharose column (2.0× 10 cm) pre-equilibrated with buŠer-B (buŠer-A containing 0.5z sodium cholate). The column was washed with 3 volumes of buŠer-B and the bound protein was eluted with buŠer-C (buŠer-A containing 0.5z sodium cholate and 0.2z Emulgen 911). The eluted fraction was dialyzed overnight against 80 volumes of buŠer-D (20 mM Tris-acetate, pH 7.2, containing 20z glycerol, and 0.2 mM DTT) at 49 C, and it was concentrated by ultraˆltration using Amicon 8050ˆtted with a PM30membrane (exclusion molecular weight, 30,000). The concentrated solution was applied to a DEAE-5PW column (0.75×7.5 cm, Tosoh corp., Tokyo) preequilibrated with buŠer-E (buŠer-D containing 0.4z Emulgen 911). The column was then washed with buŠer-E at a ‰ow rate of 1 mL W min until the absorption at 417 nm reduced to the baseline level. Chromatography was performed at room temperature and at a ‰ow rate of 1 mL W min with a linear gradient of sodium acetate from 0 to 0.2 M over 30 min in buŠer-E. The elution of P450 enzyme was monitored at 417 nm. The main peak fraction was collected and subjected to further puriˆcation with a hydroxylapatite column (0.6 ×10 cm, Koken, Tokyo) pre-equilibrated with buŠer-F (10 mM sodium phosphate buŠer, pH 7.2, containing 20z glycerol, 0.2z sodium cholate and 0.2z Emulgen 911). Chromatography was performed at room temperature and at a ‰ow rate of 0.7 mL W min with a linear gradient of sodium phosphate buŠer (pH 7.2) from 10 to 350 mM over 50 min in the presence of 20z glycerol, 0.2z sodium cholate, and 0.2z Emulgen 911. To remove Emulgen 911 from each puriˆed P450, the collected fraction was diluted with 4 volumes of 20z glycerol and applied to an open column packed with Bio-Gel HT (1.0×3.0 cm, Bio-Rad Laboratories, Richmond) which had been pre-equilibrated with buŠer-G (10 mM sodium phosphate buŠer, pH 7.2, containing 20z glycerol and 0.05z sodium cholate). The column was washed with buŠer-G until the absorption of Emulgen 911 at 280 nm disappeared. Eventually, the bound P450 enzyme was eluted by buŠer-H (350 mM sodium phosphate buŠer, pH 7.2, containing 20z glycerol and 0.05z sodium cholate). The purity of each P450 preparation during the puriˆcation process was checked by electrophoresis using 10z SDS-polyacrylamide gel and staining with 0.05z Coomassie Blue.
Preparation of antibody: Each puriˆed P450 enzyme was diluted to a protein concentration of 10-50 mg W mL with saline and mixed with an equal volume of complete Freund's adjuvant to produce a homogeneous emulsion. Emulsiˆed antigen was subcutaneously injected into female Japanese White rabbits (2-2.5 kg) obtained from Biotech (Saga, Japan) as described previously. 18) To raise and maintain the production of high titer antiserum, rabbits were then injected intravenously with 10-50 mg of the same P450 dissolved in saline at 2week intervals after theˆrst immunization. Four weeks after theˆrst booster, we started drawing blood from an ear artery. Every lot of antiserum was veriˆed for its inhibitory potency and speciˆcity using pooled human liver microsomes and selected E. coli-expressed P450 enzyme. The speciˆcity of resultant antibodies was also veriˆed using an immunoblotting method with pooled human liver microsomes and puriˆed P450s expressed in E. coli.
Puriˆcation of anti-CYP2C19 antibody by immunoabsorption: Due to the structural relatedness of CYP2C subfamily enzymes, the raised anti-CYP2C19 may show weak cross reactivity with CYP2C9, which is relatively abundant in human liver microsomes. To improve the inhibitory speciˆcity of the anti-CYP2C19 antibody, we used an immunoabsorption approach as described herein. Every lot of antiserum derived from CYP2C19-immunized rabbits was analyzed for its potency to inhibit human liver microsomal (S )mephenytoin 4?-hydroxylation. Antiserum, which strongly inhibited (S )-mephenytoin 4?-hydroxylation, was selected and subjected to immunoabsorption treatment. To minimize the cross reactivity of anti-CYP2C19 toward CYP2C9, one mL of anti-CYP2C19 serum was incubated with the membrane fraction containing 0-200 pmol of CYP2C9 expressed in E. coli. The incubation was performed at room temperature and facilitated with 60 min of shaking. After the incubation, the mixture was subjected to ultracentrifugation (105,000 g for 30 min). Nonspeciˆc immunogloblins that bound to the membrane fraction could simply be removed as a pellet after ultracentrifugation. The inhibitory activity of anti-CYP2C19, which had been improved, was retrieved in the supernatant fraction. The speciˆcity of this immunoabsorption-treated anti-CYP2C19 was veriˆed by immunoblotting assay and probe reactions described in the following section.
Characterization of antibody: To characterize the inhibitory potency and speciˆcity of resulting antibodies, 1-20 mL of each antiserum (or immunoabsorptiontreated anti-CYP2C19) was added to 450 mL of 0.1 M potassium phosphate buŠer, pH 7.4, containing 100 or 200 mg of pooled human liver microsomes or 10 pmol of E. coli-expressed CYP1A1 or CYP1A2. The mixture was preincubated for approximately 10 min at room temperature. Reactions were initiated by the addition of a targeted probe substrate followed by 400 mmol of NADPH and were performed at 379 C for 15 to 60 min depending on the probe substrate used. A control reaction was performed by replacing the antiserum with non-immune rabbit serum. Each particular P450 enzyme-mediated probe reaction was performed according to previous reports [19] [20] [21] [22] [23] [24] [25] [26] with slight modiˆcations. The inhibitory potency of the antibody was expressed in terms of the percentage of catalytic activity in the presence of immune serum against control activity in the presence of non-immune serum. All determinations were performed in duplicate and data are expressed as the mean.
Reactions were quenched by the addition of acid, alkali solution, ethyl acetate or dichloromethane. For 7-ethoxyresoruˆn O-dealkylation and coumarin 7hydroxylation, the reactions were quenched by methanol and 4z perchloric acid respectively. The terminated mixtures were centrifuged and supernatant was measured directly using a ‰uorescence detector as described elsewhere. 19, 20) Diclofenac 4?-hydroxylation and bufuralol 1?-hydroxylation are quenched with hydrochloric acid and sodium hydroxide solution respectively and then extracted with ethyl acetate (2-3 mL). Taxol hydroxylation, chlorzoxazone 6?-hydroxylation, and testosterone 6b-hyroxylation; were quenched and extracted with ethyl acetate (2-3 mL). The resulting organic phase was evaporated under reduced pressure at 409 C. The dry residue was then dissolved in mobile phase for HPLC. For (S )-mephenytoin 4?hyroxylation, the quenched reaction mixture was treated with 3 mL of dichloromethane for extraction. The organic phase was evaporated under reduced pressure without heating. The dry residue was dissolved in mobile phase for HPLC.
Results
Purity of the antigen P450s: The cDNA-expressed P450s were puriˆed to homogeneity, as judged by electrophoresis ( Fig. 1) . However, puriˆed CYP1A1 degraded rapidly after puriˆcation and during storage. The degraded protein fraction has a lower molecular weight than the intact protein. We found that the degradation continued gradually during storage and the den- sity of the degraded protein band increased during the course of storage (data not shown). The speciˆc content of the puriˆed P450s ranged from 9.65 to 18.26 nmol W mg of protein, except that of CYP1A1 ( Table 1) . These highly puriˆed P450s were used as antigen for antibody production. Antibody production and characterization: In most cases, the rabbits started to produce high titer inhibitory antibody from 6 to 8 weeks after the primary immunization of antigen, as determined by inhibitory potency assay (Fig. 2) . Titers of the antibody were well maintained throughout the production schedule if rabbits were boosted su‹ciently (10-50 mg W dose) every two or three weeks. Rabbit 1 and rabbit 2 shown in Fig. 2 immunized with the same amount of puriˆed CYP2C9 as antigen prepared in a similar manner and treated with the same immunization schedule, produced antiserum having similar inhibitory titer. Rabbit 3, which had been immunized with double the amount, produced a relatively higher titer antiserum at week 6. Nevertheless, the inhibitory potency of the antiserum of these three rabbits reached a plateau at week 8. However, further study of the speciˆcity of these antiserum lots showed that the rabbit 1 and rabbit 2 antiserum produced speciˆc inhibition when incubated with pooled human microsomes ( Table 2 ). Sera of rabbit 3 had an inhibitory eŠect not only on the corresponding antigen's reaction (CYP2C9 probe reaction) but also on human liver microsomal (S )-mephenytoin 4?-hydroxylation (CYP2C19 probe reaction) and to a lesser extent, taxol 6a-hydroxylation (CYP2C8 probe reaction, data not shown). A similar phenomenon occurred using rabbits selected for producing antibodies for each P450 enzyme. Thus, every lot of serum has been analyzed for its inhibitory potency and speciˆcity.
Anti-CYP2C8, anti-CYP2C9, and anti-CYP2C19 antibodies: Rabbits immunized with CYP2C8 or CYP2C9 were found to produce speciˆc antiserum, the inhibitory eŠect of which is antigen-speciˆc despite the extensive sequence homology (78z at the amino acid level) between these two antigens. Anti-CYP2C8 potent-ly inhibited human liver microsomal taxol 6a-hydroxylation but showed no inhibitory eŠect on other probe reactions being investigated (Fig. 3A) . Anti-CYP2C9 inhibited human liver microsomal diclofenac 4?-hydroxylation, the CYP2C9 probe reaction, in a dose-respon- sive manner (Fig. 3B) . When an over-dose of anti-CYP2C9 was added to human liver microsomes (À10 mL W 100 mg microsomes), taxol 6a-hydroxylation was weakly inhibited, but the inhibitory level was low and the rest of the tested probe reactions were not unaŠected.
CYP2C19-immunized rabbits could not provide antisera with a speciˆc inhibitory eŠect if the antisera were not immunoabsorbed before use ( Table 3) . Antiserum derived from CYP2C19-immunized rabbits potently inhibited human liver microsomal (S )-mephenytoin 4?-hydroxylation (approximately 75z inhibition at 5 mL W 100 mg pooled human liver microsomes). However, this antiserum also moderately inhibited human liver microsomal diclofenac 4?-hydroxylation when the serum volume added to human liver microsomes was doubled (10 mL W 100 mg pooled human liver microsomes (Fig. 3C) . A preliminary study was designed to determine the optimum conditions for immunoabsorption of the antiserum. The results showed that 100 pmol of cDNA-expressed CYP2C9 (membrane bound form) together with 1 mL of anti-CYP2C19; provided the best conditions in which most of the non-speciˆc immunoglobulin could be easily removed from the serum. The resultant (post-treated) sera retained most of its inhibitory potency toward human liver microsomal (S )-mephenytoin 4?-hydroxylation and the non-speciˆc inhibitory eŠect toward human liver microsomal diclofenac 4?-hydroxylation was reduced ( Table 3) .
Anti-CYP2C19 was pooled, immunoabsorbed and characterized. Inhibitory speciˆcity of treated anti-CYP2C19 antibody was remarkably increased. Treated anti-CYP2C19 antibody inhibited human liver microsomal (S )-mephenytoin 4?-hydroxylation at the concentration of lower than 2 mL W 100 mg microsomes (Fig. 3C) .
Anti-CYP1A1 and anti-CYP1A2 antibodies: For the speciˆcity of antisera collected from CYP1A1 or CYP1A2 immunized-rabbits, the inhibitory eŠect of antisera on 7-ethoxyresoruˆn O-dealkylation, were determined ( Fig. 4A and 4B) . Both anti-CYP1A1 and anti-CYP1A2 inhibitory activity appeared to be speciˆc to the corresponding antigen. Anti-CYP1A1 was found to inhibit strongly the 7-ethoxyresoruˆn O-dealkylation activity of cDNA-expressed the CYP1A1. This antibody 4 . Inhibitory studies using anti-CYP1A1 and anti-CYP1A2 antibodies. A: speciˆcity of anti-CYP1A1 veriˆed with its inhibition of E. coli-expressed-CYP1A1 () and CYP1A2 () 7-ethoyresoruˆn O-dealkylation. B: speciˆcity of anti-CYP1A2 veriˆed by its inhibition of E. coli expressed-CYP1A1 () and CYP1A2 () 7-ethoyresoruˆn O-dealkylation. Antibody was added as indicated to 10 pmol of CYP1A1 or CYP1A2 and preincubated for 10 minutes at 379 C. Each probe reaction was initiated by addition of 400 mmol of NADPH and 20 nmol of 7-ethoxyresoruˆn. The inhibitory potency of antiserum was measured and expressed in terms of the percentage of catalytic activity in the presence of immune serum against control activity in the presence of non-immune serum.
was, if overdosed (À10 mL serumW 10 pmol of P450), acted to a much lesser extent to inhibit CYP1A2, which has the highest sequence homology with CYP1A1. Whereas, anti-CYP1A2 markedly inhibited the CYP1A2 activity expressed in E. coli but did not inhibit CYP1A1 enzymatic activity (Fig. 4B) . These two antibodies were further characterized by analyzing the inhibitory speciˆcity in pooled human liver microsomes ( Fig. 5A and 5B) . The anti-CYP1A2 inhibitory proˆle was shown to be speciˆc to antigen (Fig. 5B) . Anti-CYP1A2 speciˆcally inhibited human liver microsomal 7-ethoxyresoruˆn O-dealkylation activity and did not interfere with any other P450 probe reactions being investigated. Anti-CYP1A1, whose inhibitory eŠect appeared to be CYP1A1-speciˆc, was found not only to inhibit CYP1A1-mediated activity but also to inhibit strongly human liver microsomal taxol 6a-hydroxylation (CYP2C8 probe reaction). Human liver microsomal 7-ethoxyresoruˆn O-dealkylation, which is mediated by hepatic available CYP1A2, was not inhibited by anti-CYP1A1.
Anti-CYP2A6, anti-CYP2D6, anti-CYP2E1, and anti-CYP3A4 antibody: Rabbits immunized with puriˆed CYP2A6, CYP2D6, CYP2E1, and CYP3A4 were found to produce speciˆc antibodies. Anti-CYP2A6 potently inhibited human liver microsomal coumarin 7-hydroxylation and showed no inhibitory eŠect toward other probe reactions (Fig. 6A) . Anti-CYP2D6 speciˆcally inhibited human liver microsomal bufuralol hydroxylation with no inhibitory eŠect on other probe reactions (Fig. 6B) . The speciˆcity of anti-CYP2E1 was also found to be high, and it inhibited human liver microsomal chlorzoxazone 6?-hydroxylation speciˆcally (Fig. 6C) . A relatively high percentage of uninhibited chlorzoxazone 6?-hydroxylation activity was observed, suggesting the contribution of other P450s. Anti-CYP3A4 showed a speciˆc inhibitory eŠect toward human liver microsomal testosterone 6bhydroxylation and no inhibition of other probe reactions investigated (Fig. 6D ).
Discussion
From our previous study on antibody production, we realized that boosting rabbits with 100 mg W dose or more of puriˆed antigen might result in a high titer but low speciˆcity antibody (unpublished data). On the other hand, boosting rabbits with 50 mg W dose or less of puried antigen usually resulted in a su‹ciently high titer and speciˆc antibody. Our present study as shown in Table 2 reconˆrmed that rabbits boosted with lower dose (25 mg W dose) of antigen produced speciˆcity antibody but rabbit boosted with higher dose (50 mg W dose) failed eventually. This result indicated that speciˆcity of raised antibody is not solely depending on the purity of antigen but also the dosage of antigen applied during the production course.
By immunizing rabbits with puriˆed antigens at concentrations from 10 to 50 mg W dose, we have successfully developed speciˆc antibodies against major human P450s. We also learned that speciˆc pathogen-free animals maintained in a clean environment during the course of antibodies production provided a better opportunity for obtaining speciˆc antibodies, compared with those conventionally raised and maintained.
Using a heterologous expression system in E. coli, we expressed 9 major human P450 enzymes and puriˆed them. We believe the preparation of a puriˆed P450 enzyme, which maintains its stereo-conformation, is important for raising antibody that precisely recognizes the structural conformation and can inhibit the enzymatic activity of the corresponding antigen. In a previous attempt, in which denatured P450 was injected into rabbits, raised antibodies did not show potent inhibition (data not shown). Therefore, we believe that the injection of P450 enzymes that maintains their stereoconformation is a crucial factor when raising inhibitory antibodies. Belloc et al. found that antibodies raised by puriˆed P450s without typical CO-diŠerence that recognized the respective antigens in immunoblotting but showed no inhibitory eŠect against the antigen's enzymatic activity in most cases. 27) Except anti-CYP1A1 and anti-CYP2C19, all the resultant antibodies recognized a single protein band in human liver microsomes that showed the same mobility as the respective cDNA-expressed P450. Nevertheless, the cross reactivity of anti-CYP1A1 Fig. 6 . Inhibitory studies of rabbit sera. A: speciˆcity of anti-CYP2A6 to inhibit human liver microsomal coumarin 7-hydroxylation. B: speciˆcity of anti-CYP2D6 to inhibit human liver microsomal bufuralol 1?-hydroxylation. C: speciˆcity of anti-CYP2E1 to inhibit human liver microsomal chlorzoxazone 6?-hydroxylation. D: speciˆcity of anti-CYP3A4 to inhibit human liver microsomal testosterone 6b-hydroxylation. Antibody was added to 100 mg of human liver microsomes or 10 pmol of expressed CYP1A1 and pre-incubated for 10 minutes at 379 C. Each probe reaction was initiated by addition of 400 mmol of NADPH and substrate [20 nmol of 7-ethoxyresoruˆn (CYP1A1,  and CYP1A2, ), 1 mmol of coumarin (CYP2A6, ×), 5 nmol of taxol (CYP2C8, $), 200 nmol of diclofenac (CYP2C9, #), 25 nmol of (S )-mephenytoin (CYP2C19, ), 20 nmol of bufuralol (CYP2D6, ), 250 nmol of chlorzoxazone (CYP2E1, ), 1 mmol of testosterone (CYP3A4, )]. The inhibitory potency of antiserum was measured and expressed as the percentage of catalytic activity in the presence of immune serum against control activity in the presence of non-immune serum. Antibodies  CYP1A1  CYP1A2  CYP2A6  CYP2C8  CYP2C9  CYP2C19  CYP2D6  CYP2E1  CYP3A4 anti toward CYP2C8 remains undeˆned. We assume that anti-CYP1A1 will be used as a tool for distinguishing CYP1A1 from CYP1A2 but not CYP2C8. If Anti-CYP1A1 applied for reaction phenotyping inhibited a tested reaction, we would have to use anti-CYP2C8 to set up a parallel inhibition test in order toˆnd out which P450 is responsible for the reaction. Moreover, the cross reactivity of raised antibodies were not yet examined with other minor P450 isozymes, including CYP2B6, CYP3A5 and CYP3A7. To develop antibody for other P450 isozymes and to check the cross reactivity of the raised antibodies on other P450 are parts of our future studies.
In conclusion, these inhibitory antibodies will serve as useful tools for evaluating the contribution of major individual P450 enzymes to drug metabolism.
